PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 6, 2026Advanced Functional Materials0 citations

Precisely Controllable Y‐Shaped DNA Nanomachine‐Immunoassay System: Noninvasive Monitoring of Tumor Progression and Metastasis

View Full Paper
PJPengjun JiangZFZiqiang FanYWYue Wang

Key Points

  • To develop a DNA nanomachine immunoassay system for early cancer diagnosis and monitoring of tumor progression.
  • Developed a Y-shaped DNA nanomachine immunoassay system (DYN@IA) for detecting circulating tumor cells.
  • Utilized a biotin-streptavidin system for triggering conformational changes in DNA scaffolds.
  • Conducted practical validation using primary lung cancer cells and analyzed 145 clinical samples.
  • Achieved simultaneous detection of diverse circulating tumor cells within 45 minutes.
  • Reached a sensitivity of 88% and specificity of 96% in lung cancer early screening.
  • Provided results consistent with imaging and pathology diagnoses.

Abstract

ABSTRACT Herein, we developed a DNA scaffold‐mediated Y‐shaped DNA nanomachine immunoassay system (DYN@IA) that enables a homogeneous electrochemical immunoassay for the simultaneous detection of epithelial and mesenchymal circulating tumor cells, applicable to early cancer diagnosis and monitoring. The double Y‐shaped DNA design facilitated the self‐assembly of metal ion‐mediated DNA nanomachines, forming stable and controllable functional nanomachines for the recognition of heterogeneous CTCs. Antigen‐antibody binding formed steric hindrance and exerted local tension on the DNA scaffolds through the biotin‐streptavidin system, triggering conformational changes in the double‐stranded DNA, and releasing Ag + and Hg 2+ . Finally, the practical validation was conducted using primary lung cancer cells (pre‐ and post‐metastasis) and the surface targets epithelial cell adhesion molecule and vimentin. The results indicated that simultaneous detection of different CTCs was achieved within 45 min, with a limit of detection down to the single‐cell level. Additionally, the method was successfully applied to 145 clinical samples for lung cancer early screening and identification of distant metastasis (achieving sensitivity and specificity of 88% and 96%), with results highly consistent with imaging findings and pathology diagnoses. The DYN@IA design outperformed conventional immunoassays by significantly shortening reaction time while improving sensitivity and signal‐to‐noise ratio, providing insights for tumor screening and monitoring.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jiang et al. (2026) studied this question.

synapsesocial.com/papers/69fa979b04f884e66b531971https://doi.org/10.1002/adfm.75631
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Steric Hindrance-Mediated Enzymatic Reaction Enable Homogeneous Dual Fluorescence Indicators Aptasensing of Hepatocellular Carcinoma CTCs2024 · 13 citations
  2. 2Capture of Heterogeneous Circulating Tumor Cells in Colorectal Cancer Patients on an Immunomagnetic and Anti-Nonspecific Adsorption Platform2022 · 37 citations
  3. 3Next-Generation Liquid Biopsies: Embracing Data Science in Oncology2020 · 70 citations
  4. 4Potential-Resolved Multicolor Electrochemiluminescence for Multiplex Immunoassay in a Single Sample2018 · 364 citations
  5. 5A Chiral‐Nanoassemblies‐Enabled Strategy for Simultaneously Profiling Surface Glycoprotein and MicroRNA in Living Cells2017 · 136 citations